Navigation Links
Mylan Announces Appointment of Harry A. Korman as President, North America
Date:10/2/2007

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Harry A. (Hal) Korman to the position of President, North America following the completion of the acquisition of Merck Generics Group today.

In his new role, Mr. Korman will continue to drive growth and development of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the U.S. In addition, he will oversee GenPharm, Inc., the former Canadian subsidiary of Merck Generics and the fourth largest generics company in Canada, and UDL Laboratories, Inc., the U.S. leader in unit dose packaging.

Mr. Korman previously served as President of MPI, as well as Senior Vice President of Mylan Laboratories Inc. Since joining Mylan through its acquisition of UDL Laboratories in 1996, he has served the Company in several capacities of increasing responsibility, including President of UDL and Vice President of Sales and Marketing for MPI.

Mylan Vice Chairman and CEO Robert J. Coury commented: "Hal has played a critical role in our success to date and is a key member of our management team. He has been instrumental in building Mylan into the leader in quality generics in the U.S. that we are today. Since Hal's appointment as President of MPI, he has proven his ability to meet or exceed every objective set for him and he will certainly rise to these new responsibilities. By bringing these North American businesses together under Hal's leadership, we will be best placed to identify and execute on growth and synergy opportunities in the region. I am confident that we will continue to go from strength to strength in North America."

Mr. Korman said: "It's been an honor to be part of Mylan for the last 20 years as the company has grown from a leader in the U.S. to a new global leader in generics and specialty pharmaceuticals. I am also proud to be part of a management team that truly shares one vision for the new Mylan. As we look ahead to the future, there have never been greater opportunities to take the company forward and continue to provide the best quality products and service to our customers."

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt ... decrease overall productivity and performance in the workplace. The goal of Clearview Resolution Services ... few weeks of April, Clearview Resolution Services will be shutting down the office early ...
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology: